Table 3

Changes in Quality of Life (Assessed by the MLHFQ), Sitting SBP, and HR in Patients Not Treated With Angiotensin-Converting Enzyme Inhibitors

ValsartanPlacebop Value
Change in MLHFQ score (LSM ± SEM)
One year−4.15 ± 1.78 (n = 86)1.01 ± 2.11 (n = 73)0.047*
Two years−1.07 ± 2.30 (n = 48)5.62 ± 3.18 (n = 27)0.078
Last observation−0.98 ± 1.71 (n = 112)3.17 ± 1.98 (n = 97)0.095
SBP (mm Hg) (LSM ± SEM)
One year−7.5 ± 1.1 (n = 150)−0.5 ± 1.2 (n = 133)< 0.001*
Two years−8.4 ± 1.8 (n = 97)0.6 ± 2.0 (n = 76)0.001*
Last observation−8.1 ± 1.2 (n = 184)−3.2 ± 1.2 (n = 180)0.004*
HR (beats/min) (LSM ± SEM)
One year−2.4 ± 0.8 (n = 150)−0.3 ± 0.8 (n = 133)0.065
Two years−2.4 ± 1.0 (n = 97)−3.6 ± 1.2 (n = 76)0.430
Last observation−0.6 ± 0.8 (n = 184)−0.6 ± 0.8 (n = 180)0.974

HR = heart rate; LSM = least squares mean; MLHFQ = Minnesota Living With Heart Failure Questionnaire; SBP = sitting systolic blood pressure.

  • * Statistically significant at p < 0.05. Data are presented as the least squares mean (LSM) change ± SEM by analysis of co-variance.